📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 1 — Container/Carton/Patient Labeling (TILA-278)
Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
Document ID: M1-LBL
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): 21 CFR 201/208; SPL
The submission labeling set for TILA-278 beyond the prescribing information: immediate-container and carton labels (proprietary/nonproprietary name, strength, route [subcutaneous], storage, lot/expiry), a Medication Guide / Patient Package Insert, and, for the device presentation, Instructions for Use. In a US submission these are also provided as Structured Product Labeling (SPL) XML. 21 CFR 201; 208; SPL R8.
TILA-278 (proposed proprietary name TILVARA; proposed nonproprietary name tilazumig, an anti-TL1A antagonist / IL-22R agonist bispecific IgG1 monoclonal antibody produced in a Chinese hamster ovary [CHO] cell line) is a licensed biological product; its container and package labeling are therefore governed by the biologics labeling provisions of in addition to the prescription-drug labeling requirements of and the content/format rules of . The labeling artifacts filed at eCTD 1.14 are internally consistent with, and derived from, the draft Prescribing Information (eCTD 1.14.1.3) and the annotated labeling (eCTD 1.14.1.2). As a licensed biologic, the finished-product labels bear the of Virtual Biopharma Inc. and the FDA-designated four-letter suffix appended to the proper name in accordance with the Agency's nonproprietary-naming policy for biological products.
No comments yet. Be the first to say something!
Two commercial presentations are labeled, each a single-dose combination product (21 CFR Part 4): a single-dose prefilled syringe and a single-dose prefilled autoinjector, both delivering 450 mg/3 mL (150 mg/mL) for subcutaneous administration. Storage, strength, route, container-closure, and device-performance statements on the labels are traceable to Module 3.2.P (drug product and container-closure system), Module 3.2.P.7 / device documentation, and the stability program.
The immediate containers are small-volume prefilled devices; abbreviated content is applied under the small-container provisions of 21 CFR 201.10(i) and 610.60(b), retaining only the information essential to safe use while directing the user to the carton and enclosed labeling for the full content. Each immediate-container label carries:
| Element | Content on immediate container |
|---|---|
| Proprietary / proper name | TILVARA (tilazumig) injection |
| Strength / fill | 450 mg/3 mL (150 mg/mL) |
| Route | For subcutaneous use only |
| Dosing units | Single-dose; discard unused portion |
| Legend | Rx only |
| Sterility / preservative | Sterile; preservative-free |
| Traceability | Lot number; Expiration date (MMM YYYY) |
| Storage | Store 2°C–8°C; do not freeze; do not shake |
| Responsible firm | Virtual Biopharma Inc.; U.S. License No. [to be assigned] |
| Machine-readable identifier | Linear/2D bar code encoding the NDC per 21 CFR 201.25 |
Because label real estate on the syringe barrel and the autoinjector body is limited, the proper name (with suffix), strength, route, lot, and expiry are prioritized so the drug can be identified and its integrity verified at the point of administration; the plunger-rod flag and needle-cap components are labeled consistent with the device design outputs. 21 CFR 610.60(b); 201.10(i); 201.25.
Each presentation is supplied as a carton of 1. The carton (package) label carries the full complement of biologics package-label content required by 21 CFR 610.61, together with the prescription-drug content of 21 CFR 201.100:
Storage statements on the carton reconcile exactly with the "How Supplied/Storage and Handling" section of the Prescribing Information and with the stability-derived shelf life and excursion allowances. 21 CFR 610.61; 201.100; 201.25.
A determination under 21 CFR Part 208 was made as to whether a Medication Guide is warranted, evaluating the product against the Part 208 criteria (patient labeling could help prevent serious adverse effects; the product carries serious risks of which patients should be informed; and adherence to directions is essential to effectiveness). The clinically important risks of an immunomodulatory bispecific antibody in this class — infections (including consideration of tuberculosis and hepatitis B reactivation), hypersensitivity and immunogenicity, injection-site reactions, and the need to avoid live vaccines — are conveyed through routine labeling (Prescribing Information Sections 5.1–5.4) and patient counseling. Consistent with the REMS assessment (M1-REMS), no important identified risk requiring elements to assure safe use was identified; accordingly, the sponsor proposes FDA-approved Patient Information under 21 CFR 201.57(a)(17) rather than a Medication Guide, while deferring to the Agency's determination on whether Part 208 patient labeling is required.
The Patient Information is written in plain, non-technical language and covers: what TILA-278 is and its mechanism in ulcerative colitis (blocking TL1A-driven intestinal inflammation while supporting mucosal-barrier healing through the IL-22 receptor); the approved use (induction of clinical remission in adults with moderately to severely active UC); what to tell the healthcare provider before starting (signs of infection, tuberculosis exposure, hepatitis B status, planned vaccinations, pregnancy or breastfeeding); how the medicine is given (subcutaneous injection at Weeks 0, 2, 4, and 8, with response assessed at Week 12); possible side effects, with instructions to seek care for serious infection or allergic reactions; how to store the product refrigerated and protected from light; and general information on safe use. 21 CFR 208; 201.57(a)(17).
Because both commercial presentations are drug-device combination products (21 CFR Part 4), a presentation-specific Instructions for Use (IFU) accompanies each of the prefilled syringe and the autoinjector. The IFU content was developed and validated under a usability-engineering process (IEC 62366-1 and FDA human-factors guidance), with a use-related risk analysis and a human-factors validation study in representative users (patients and caregivers) performing simulated self-injection; the supporting design controls, use-related risk analysis, and validation results are provided in the device/combination-product documentation (M3-DEV) and Module 3.2.P.7. The IFU reconciles with Dosage and Administration (Section 2.3) of the Prescribing Information and includes:
21 CFR Part 4; 4/820.30; IEC 62366-1; ISO 11608.
All content of labeling is provided in SPL R8 XML per the FDA SPL Implementation Guide and submitted within eCTD Module 1.14. This comprises the Content of Labeling SPL (the full Prescribing Information rendered with LOINC-coded sections), the product/indexing SPL carrying the structured product data elements (NDC package and product codes, proprietary and proper name with suffix, dosage form [injection], route [subcutaneous], strength [150 mg/mL], and packaging descriptions for each presentation), and the establishment registration and drug-listing SPL identifying the manufacturing, testing, packaging, and labeling establishments consistent with FDA Form 356h and Module 3.2.A.1. The SPL files provide the machine-readable, exchange-ready representation of the human-readable container, carton, and patient labeling described above, and are maintained under version control across the product lifecycle. SPL R8; 21 CFR 207 (registration and listing).
Every quantitative and qualitative statement across the immediate-container labels, carton labels, Patient Information, Instructions for Use, and SPL is reconciled against a single source: strength, fill volume, route, and presentation trace to Module 3.2.P; storage conditions and the room-temperature excursion allowance trace to the drug-product stability program; container-closure integrity and device essential performance trace to Module 3.2.P.7 and M3-DEV; and the naming and license statements trace to 21 CFR 610.62 and the biologics naming policy. Placeholders (NDC, U.S. License No., initial approval and revision dates) are finalized in the approved labeling. Any post-approval change to the labels or SPL is managed under the applicable reporting category (annual report, CBE-30, or prior-approval supplement) per 21 CFR 601.12. 21 CFR 601.12; 610.62.